购物车
- 全部删除
- 您的购物车当前为空
TGase2-IN-1(Compound 22)为一种具口服效力的TGase2抑制剂,其对TGase2的IC50值为1.12 μM,且对人视网膜微血管内皮细胞中TGase2的抑制作用的IC50为0.07 μM。此外,TGase2-IN-1展现出74.6%的口服生物利用度,并能有效抑制小鼠Streptozotocin诱导的糖尿病模型中视网膜血管渗漏。
TGase2-IN-1(Compound 22)为一种具口服效力的TGase2抑制剂,其对TGase2的IC50值为1.12 μM,且对人视网膜微血管内皮细胞中TGase2的抑制作用的IC50为0.07 μM。此外,TGase2-IN-1展现出74.6%的口服生物利用度,并能有效抑制小鼠Streptozotocin诱导的糖尿病模型中视网膜血管渗漏。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | TGase2-IN-1 (Compound 22) is an orally effective TGase2 inhibitor with an IC50 of 1.12 µM. It inhibits TGase2 in human retinal microvascular endothelial cells with a strikingly lower IC50 of 0.07 µM. The oral bioavailability of TGase2-IN-1 is 74.6%. Additionally, it can suppress retinal vascular leakage in a mouse model of diabetes induced by Streptozotocin. |
分子量 | 391.46 |
分子式 | C23H25N3O3 |
CAS No. | 2244702-64-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容